Vontobel Holding Ltd. Purchases 41,196 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Vontobel Holding Ltd. boosted its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 78.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,750 shares of the company’s stock after acquiring an additional 41,196 shares during the period. Vontobel Holding Ltd.’s holdings in GoodRx were worth $651,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of GDRX. GSA Capital Partners LLP purchased a new stake in GoodRx during the first quarter worth $1,638,000. Mirae Asset Global Investments Co. Ltd. boosted its position in GoodRx by 61.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock valued at $1,289,000 after purchasing an additional 68,835 shares in the last quarter. Jupiter Asset Management Ltd. purchased a new position in GoodRx in the first quarter valued at about $707,000. Liontrust Investment Partners LLP purchased a new position in GoodRx in the second quarter valued at about $520,000. Finally, ClariVest Asset Management LLC bought a new position in GoodRx in the first quarter worth about $1,091,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Down 4.3 %

GoodRx stock opened at $6.61 on Tuesday. The business’s 50-day simple moving average is $7.33 and its two-hundred day simple moving average is $7.58. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. The company has a market cap of $2.48 billion, a PE ratio of -661.00, a PEG ratio of 4.44 and a beta of 1.37. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The firm had revenue of $200.60 million during the quarter, compared to analysts’ expectations of $200.47 million. During the same quarter in the prior year, the company earned $0.02 EPS. GoodRx’s quarterly revenue was up 5.7% on a year-over-year basis. Equities analysts anticipate that GoodRx Holdings, Inc. will post 0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on GDRX shares. UBS Group lowered their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 9th. Citigroup lowered their target price on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a report on Friday, August 16th. Finally, Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.36.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.17% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.